Steps to address anti-microbial drug resistance in today’s drug discovery

Click to increase image sizeClick to decrease image size

Declaration of interest

The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

One referee declares having been a speaker for and/or has received research grants from Bayer and Merck (tedizolid), Melinta and Menarini (delafloxacin), Ferrer (ozenoxacin), AstraZeneca (avibactam), GlaxoSmithKline (gepoditacin) and Debiopharm (afabicin). He also has been member of the Governance Body of DRIVE-AB, a EU-sponsored program examining the economic aspects the discovery, development, and commercialization of novel antibiotics

Additional information

Funding

This manuscript was not funded.